| Trial ID: | L3308 |
| Source ID: | NCT01492166
|
| Associated Drug: |
Biphasic Human Insulin 30
|
| Title: |
Observational Study on Efficacy, Safety and Convenience of Using Mixtard® 30 NovoLet® Alone or Combined With OHA in Treatment of Type 2 Diabetes in Routine Clinical Practice
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: biphasic human insulin 30
|
| Outcome Measures: |
Primary: Change in fasting blood glucose (FBG)|Change in 2-hour post prandial blood glucose|Change in HbA1c (glycosylated haemoglobin)|Change in prandial glucose increment (PGI) | Secondary: Frequency of minor and major hypoglycaemia|Occurrence of Adverse Drug Reactions (ADR)
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
CHILD, ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
1935
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2006-11
|
| Completion Date: |
2007-06
|
| Results First Posted: |
|
| Last Update Posted: |
2016-12-13
|
| Locations: |
Novo Nordisk Investigational Site, Jakarta, 12520, Indonesia
|
| URL: |
https://clinicaltrials.gov/show/NCT01492166
|
